As of Nov 19, 2026, 2 of 2 active firms rate MGNX a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
MGNX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.48
Range $-0.48 – $-0.48 · 1 analysts · -17% YoY
Next period, 1 analysts expect MacroGenics Inc to earn $-0.48 a share (range $-0.48 – $-0.48), versus $-0.58 a year earlier. Full-year consensus is $-2.47, growing to $-1.70 the year after.
REVENUE · NEXT QUARTER
$8.3M
Range $1.5M – $15.0M · 1 analysts · -60% YoY
Revenue is expected to reach $8.3M (range $1.5M – $15.0M), -60.3% year-over-year. Full-year consensus is $104.5M, rising to $74.0M next year.
Top analysts covering MacroGenics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on MGNX.
#1
Mayank Mamtani
B. Riley Securities · Rank #36
Buy
$11.00+455.6% to target
Overall win rate
49%
+ Follow
#2
Silvan Tuerkcan
JMP Securities · Rank #69
Neutral
No targeton MGNX
Overall win rate
51%
+ Follow
#3
Peter Lawson
Barclays · Rank #89
Buy
$3.00+51.5% to target
Overall win rate
45%
+ Follow
#4
RB
Robert Burns
HC Wainwright & Co. · Rank #215
Neutral
No targeton MGNX
Overall win rate
42%
+ Follow
#5
SW
Stephen Willey
Stifel · Rank #474
Neutral
$5.00+152.5% to target
Overall win rate
29%
+ Follow
MGNX stock forecast FAQ
What is MGNX's average 12-month price target?+
The 2 active firms with a live target average $8.50 for MacroGenics Inc over the next 12 months, ranging from a $11.00 high to a $6.00 low, as of Nov 19, 2026.
Is MGNX stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 2 active firms as of Nov 19, 2026, 2 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for MGNX?+
The Street-high target is $11.00 (B. Riley Securities), and the Street-low is $6.00 (Barclays). The average of all 2 active-firm targets is $8.50.
How many active Wall Street firms cover MGNX?+
2 active firms have a recognized rating on MacroGenics Inc as of Nov 19, 2026, and 2 active firms carry a live 12-month price target.
Who is the most accurate analyst covering MGNX?+
Among analysts who currently cover MGNX, Mayank Mamtani of B. Riley Securities has the strongest overall Quantellect track record (Rank #36). Their current call is Buy with a $11.00 target.
What is MacroGenics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.48 per share (range $-0.48 – $-0.48) across 1 analysts. Full-year EPS is projected at $-2.47, rising to $-1.70 the following year.
How much revenue is MacroGenics Inc expected to report next quarter?+
Consensus revenue is $8.3M (range $1.5M – $15.0M). Full-year revenue is projected at $104.5M, growing to $74.0M next year.
Have analysts been upgrading or downgrading MGNX lately?+
As of Nov 19, 2026, 2 of 2 active firms rate MGNX a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their MGNX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.